Join to view full profile
Dana-Farber Cancer Institute450 Brookline AveBoston, MA 02215
Phone+1 617-632-3000
Dr. Abel is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
Columbia University Vagelos College of Physicians and SurgeonsClass of 2000
Certifications & Licensure
MA State Medical License 2003 - 2027
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014-2015, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
Clinical Trials
- Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
- Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation Start of enrollment: 2018 Jan 01
- Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS Start of enrollment: 2018 Oct 17
Publications & Presentations
PubMed
- Insurance Type and Quality of End-of-life Care in Adults <65 Years With Hematologic Malignancies.Hari S Raman, Elizabeth Packnett, Edo Banach, Ryan Ross, Tarne Lamp
Journal of Pain and Symptom Management. 2026-11-01 - Modernizing Surrogate Decision-Making to Reflect the Complexity of Cancer Care.Eric C Blackstone, David N Sontag, Deepa Rangachari, Gregory A Abel
JAMA Oncology. 2026-09-10 - Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.H Moses Murdock, Kyle Hebert, Mahasweta Gooptu, Roman Shapiro, Gregory Abel
Transplantation and Cellular Therapy. 2026-08-19
Abstracts/Posters
- Sleep Disturbance Among Patients with Myelodysplastic Syndromes and Acute LeukemiaGregory A. Abel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS StudyGregory A. Abel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Challenges Delivering and Measuring High-Quality Palliative Care for Patients With Hematologic Malignancies60th American Society of Hematology Annual Meeting - 12/1/2018
- Special Symposium on Quality60th American Society of Hematology Annual Meeting - 12/1/2018
- Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Ethical Questions Raised Over PRO Use in Cancer TrialsFebruary 11th, 2025- Study Finds Care After Donor Stem Cell Transplant Can Be Safely Shared Between Transplant Centers and Local OncologistsJanuary 9th, 2025
- For Older Patients with Blood Cancer Taking Multiple Medications, New Tool Links Use of Certain Medications to Risk of FrailtyAugust 11th, 2022
Grant Support
- The University of Massachusetts, Boston - Dana-Farber/Harvard Cancer Center U54 Comprehensive Partnership for Cancer Disparities ResearchDANA-FARBER CANCER INST2010–2027
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: